Publication:
Neuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence.

dc.contributor.authorLamanna-Rama, N
dc.contributor.authorMacDowell, K S
dc.contributor.authorLópez, G
dc.contributor.authorLeza, J C
dc.contributor.authorDesco, M
dc.contributor.authorAmbrosio, E
dc.contributor.authorSoto-Montenegro, M L
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERSAM (Salud Mental)es_ES
dc.contributor.funderMinisterio de Sanidad (España)es_ES
dc.contributor.funderFundación Alicia Koplowitzes_ES
dc.contributor.funderPlan Nacional de Drogas (España)es_ES
dc.contributor.funderInstituto de Investigación Sanitaria Gregorio Marañónes_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)es_ES
dc.date.accessioned2024-05-06T11:19:55Z
dc.date.available2024-05-06T11:19:55Z
dc.date.issued2023-04
dc.description.abstractThis study evaluates the long-term effects of a six and 14-week morphine withdrawal in rats pretreated with a cannabinoid agonist (CP-55,940, CP) during periadolescence. Wistar rats (33 males; 32 females) were treated with CP or its vehicle (VH) from postnatal day (PND) 28-38. At PND100, rats performed morphine self-administration (MSA, 15d/12 h/session). Eight groups were defined according to pretreatment (CP), treatment (morphine), and sex. Three [18F]FDG-PET brain images were acquired: after MSA, and after six and 14 weeks of withdrawal. PET data were analyzed with SPM12. Endocannabinoid (EC) markers were evaluated in frozen brain tissue at endpoint. Females showed a higher mean number of self-injections than males. A main Sex effect on global brain metabolism was found. FDG uptake in males was discrete, whereas females showed greater brain metabolism changes mainly in areas of the limbic system after morphine treatment. Moreover, the morphine-induced metabolic pattern in females was exacerbated when CP was previously present. In addition, the CP-Saline male group showed reduced CB1R, MAGL expression, and NAPE/FAAH ratio compared to the control group, and morphine was able to reverse CB1R and MAGL expression almost to control levels. In conclusion, females showed greater and longer-lasting metabolic changes after morphine withdrawal than males, indicating a higher vulnerability and a different sensitivity to morphine in subjects pre-exposed to CP. In contrast, males primarily showed changes in EC markers. Together, our results suggest that CP pre-exposure contributes to the modulation of brain metabolism and EC systems in a sex-dependent manner.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipMLS was supported by the Ministerio de Ciencia e Innovacion, Instituto de Salud Carlos III (project number PI17/01,766, and grant number BA21/00030), co-financed by the European Regional Development Fund (ERDF), "A way to make Europe"; project PID2021-128862OB-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE; CIBER de Salud Mental; Instituto de Salud Carlos III (project number CB07/09/0031), Ministerio de Sanidad (Delegacion del Gobierno para el Plan Nacional sobre Drogas, projects 2017/085, 2022/008917); and Fundacion Alicia Koplowitz. EA was supported by grants from Instituto de Salud Carlos III (Redes de Investigacion Cooperativa Orientadas a Resultados en Salud (RICORS): Red de Investigacion en Atencion Primaria de Adicciones (RIAPAd, RD21/0009/0020), Ministerio de Sanidad (Delegacion del Gobierno para el Plan Nacional sobre Drogas, 2021I043), Ministerio de Ciencia e Innovacion (PID2019-111594RB-100), UNED (Plan de Promocion de la Investigacion 2019-2021), and the European Union ' s Justice Programme-Drugs Policy Initiatives (JUST-2017-AGDRUGS-806996-JUSTSO). NLR was supported by Instituto de Investigacion Sanitaria Gregorio Maranon, "Programa Intramural de Impulso a la I+D+I 2019. MD was supported by Ministerio de Ciencia e Innovacion and Instituto de Salud Carlos III (ISCIII) (PT20/00044) and CIBER de Salud Mental, Instituto de Salud Carlos III (project number CB07/09/0031). JCL was supported by the Ministerio de Economia y Competitividad, MINECO-EU-FEDER (SAF2016-75500-R) and Ministerio de Ciencia e Innovacion (PID2019-109033RB-I00). The CNIC is supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovacion, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV2015-0505).es_ES
dc.format.page60es_ES
dc.format.volume69es_ES
dc.identifier.citationEur Neuropsychopharmacol. 2023 Apr:69:60-76.es_ES
dc.identifier.doi10.1016/j.euroneuro.2023.01.005es_ES
dc.identifier.e-issn1873-7862es_ES
dc.identifier.journalEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacologyes_ES
dc.identifier.pubmedID36780817es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19243
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI17/01/766es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BA21/00030es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2021-128862OB-100es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CB07/09/0031es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/2017/085es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/2022/008917es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD21/0009/0020es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-111594RB-100es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PT20/00044es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CB07/09/0031es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/ID2019-109033RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SEV2015-0505es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/JUST-2017-AGDRUGS-806996-JUSTSOes_ES
dc.relation.publisherversion10.1016/j.euroneuro.2023.01.005es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Imagen Avanzadaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshMorphinees_ES
dc.subject.meshSubstance Withdrawal Syndromees_ES
dc.subject.meshFemalees_ES
dc.subject.meshRatses_ES
dc.subject.meshAnimalses_ES
dc.subject.meshMalees_ES
dc.subject.meshCannabinoid Receptor Agonistses_ES
dc.subject.meshRats, Wistares_ES
dc.subject.meshFluorodeoxyglucose F18es_ES
dc.subject.meshEndocannabinoidses_ES
dc.subject.meshNeuroimaginges_ES
dc.subject.meshGlucosees_ES
dc.titleNeuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Neuroimaging revealed long-lasting_Eur Neuropsychopharmacol_2023.pdf
Size:
309.66 KB
Format:
Adobe Portable Document Format
Description:
Artículo